Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metal-Ligand Bonds02:51

Metal-Ligand Bonds

20.6K
The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
20.6K
Complexation Equilibria: The Chelate Effect01:19

Complexation Equilibria: The Chelate Effect

484
In complexation reactions, metal atoms or cations interact with ligands to form donor-acceptor adducts called metal complexes. Ligands that bind through one donor site are monodentate, ligands with two donor sites are bidentate, and those with more than two donor sites are polydentate ligands. For example, ethylene diamine is a bidentate ligand that binds through two nitrogen donor atoms, forming a five-membered ring. EDTA is a polydentate ligand that binds through four oxygen and two nitrogen...
484
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

433
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
433

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Robust Dynamic 3D Liver Spheroid Platform for (Sub)Chronic Toxicity Assessment: Metabolic Characterization of HepG2 Spheroids as a Case Study.

Toxicology·2026
Same author

Controlling Chemical Dynamics of Molecular Assemblies through Nanoconfinement: <i>o</i>-Nitrosocumene@Pd Nanocage.

The Journal of organic chemistry·2026
Same author

Evaluation of the Pharmaceutical Equivalence of Lidocaine and Prilocaine Creams.

Pharmaceutics·2026
Same author

Link between Spin-Orbit Relativity and Magnetically Induced Current Densities in Heavy-Atom Hydrides: <i>trans</i>-Ligand Influence.

JACS Au·2026
Same author

Pyrazinamide-derived 1,2,3-triazoles: Antimicrobial evaluation, selective antimycobacterial activity and mechanism of action insights.

European journal of medicinal chemistry·2026
Same author

Triphenylene chromophore enhances emission in Au/Cu heterometallic complexes.

Dalton transactions (Cambridge, England : 2003)·2026

Related Experiment Video

Updated: Jun 14, 2025

Author Spotlight: Advances in Evaluating Human Lung Epithelial Cells' Response to Metal-Organic Frameworks
04:53

Author Spotlight: Advances in Evaluating Human Lung Epithelial Cells' Response to Metal-Organic Frameworks

Published on: May 26, 2023

876

Cyclodextrin-Based Metal-Organic Framework as an Application Platform for Bioactive Ruthenium(III) Complexes.

Mahya Asgharian Marzabad1,2,3, Sára Kollárová1, Fangfang Pan4

  • 1Department of Chemistry, Faculty of Science, Masaryk University, Kamenice 5, 62500 Brno, Czechia.

Inorganic Chemistry
|May 23, 2025
PubMed
Summary

Ruthenium(III) complexes show anticancer potential but face delivery challenges. Encapsulating these metallodrugs in cyclodextrin-based metal-organic frameworks (CD-MOF-1) enhances efficacy and reduces toxicity for improved cancer therapy.

More Related Videos

HKUST-1 as a Heterogeneous Catalyst for the Synthesis of Vanillin
11:15

HKUST-1 as a Heterogeneous Catalyst for the Synthesis of Vanillin

Published on: July 23, 2016

10.2K
Author Spotlight: Accelerating Discovery in Microporous Material Chemistry
07:20

Author Spotlight: Accelerating Discovery in Microporous Material Chemistry

Published on: October 6, 2023

3.5K

Related Experiment Videos

Last Updated: Jun 14, 2025

Author Spotlight: Advances in Evaluating Human Lung Epithelial Cells' Response to Metal-Organic Frameworks
04:53

Author Spotlight: Advances in Evaluating Human Lung Epithelial Cells' Response to Metal-Organic Frameworks

Published on: May 26, 2023

876
HKUST-1 as a Heterogeneous Catalyst for the Synthesis of Vanillin
11:15

HKUST-1 as a Heterogeneous Catalyst for the Synthesis of Vanillin

Published on: July 23, 2016

10.2K
Author Spotlight: Accelerating Discovery in Microporous Material Chemistry
07:20

Author Spotlight: Accelerating Discovery in Microporous Material Chemistry

Published on: October 6, 2023

3.5K

Area of Science:

  • Materials Science
  • Nanotechnology
  • Oncology

Background:

  • Ruthenium(III) complexes offer anticancer properties with lower toxicity than platinum drugs.
  • Challenges include poor solubility, stability, and non-specific delivery of ruthenium(III) complexes.
  • Metal-organic frameworks (MOFs) are explored as delivery systems to enhance metallodrug efficacy.

Purpose of the Study:

  • To investigate the incorporation of a ruthenium(III) complex (RuC) into γ-cyclodextrin (γ-CD) derived MOFs (CD-MOF-1).
  • To evaluate the *in vitro* anticancer efficacy and cytotoxicity of the RuC-CD-MOF-1 drug delivery system.
  • To assess the potential of RuC-CD-MOF-1 as a metallodrug delivery platform.

Main Methods:

  • Synthesis of CD-MOF-1 using γ-cyclodextrin and potassium ions.
  • Encapsulation of a bioactive ruthenium(III) complex (RuC) within the CD-MOF-1 structure.
  • In vitro viability studies using HepG2 hepatoblastoma cell spheroids to assess cytotoxicity and efficacy.

Main Results:

  • The RuC-CD-MOF-1 system demonstrated effective suppression of cancer cell viability.
  • A slow, gradual release of RuC from the MOF over 10 days was observed.
  • The encapsulated RuC significantly reduced acute cytotoxic effects compared to the naked RuC.

Conclusions:

  • RuC-CD-MOF-1 functions as an effective drug delivery platform for metallodrugs.
  • The system enhances therapeutic efficacy by providing sustained release and reducing host toxicity.
  • This approach holds promise for developing optimized metallodrug-based cancer therapies.